Clinical Trial

A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

Study acronym: KLK2-comPAS
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in combination with best supportive care (BSC) as compared to placebo with BSC in participants with metastatic castration-resistant prostate cancer (mCRPC; a stage of cancer that has spread beyond the prostate gland and is no longer responding to hormone therapies).
Protocol Amendment History 7 changes
notable Enrollment increased: 663 -> 1203 participants 2026-08-01
minor Completion moved earlier: 2028-10-18 -> 2028-08-18 2026-08-01
notable Trial sites expanded: 168 -> 172 locations 2026-07-07
minor Completion pushed: 2027-12-29 -> 2028-10-18 2026-07-07
notable Primary completion moved earlier: 2028-05-30 -> 2027-12-29 2026-06-06
minor Completion moved earlier: 2028-05-30 -> 2027-12-29 2026-06-06
notable Trial sites expanded: 163 -> 166 locations 2026-05-09
Trial Details
NCT Number NCT07164443
Lead Sponsor Janssen Research & Development, LLC
Conditions Metastatic Castration-resistant Prostate Neoplasms
Enrollment 1,203 participants
Start Date 2025-09-02
Primary Completion 2027-12-29 (estimated)
Study Completion 2028-08-18 (estimated)
Updated on ClinicalTrials.gov 2026-07-31